The World Hepatitis Alliance's Hepatitis Delta Global Landscape Survey is now live, and your participation is crucial. By taking just a few minutes to complete this survey, you'll be contributing to a global effort to gather comprehensive data that can drive meaningful action. Together, we can push for better awareness, more comprehensive screening, and stronger support systems for those impacted by Hepatitis Delta. Click the link below to make your voice heard! 🌐 Vir is a sponsor of the Hepatitis Delta Global Landscape Survey https://bit.ly/4eS3hvb
Vir Biotechnology, Inc.
Biotechnologieforschung
San Francisco, California 32.481 Follower:innen
Powering the Immune System to Transform Lives
Info
Vir Biotechnology, Inc. (in Europe, Humabs BioMed, https://bit.ly/46lQGN2) is an immunology company focused on powering the immune system to address unmet patient needs in infectious disease and beyond. Our powerful R&D engine combines our proprietary monoclonal antibody (mAb) platform with machine learning and artificial intelligence-enhanced capabilities, enabling us to engineer our rich database of human antibodies and deliver transformative medicines for diseases with significant global burden. Our current pipeline consists of multiple clinical candidates targeting hepatitis B and hepatitis delta viruses and human immunodeficiency virus, including a potential functional cure for chronic hepatitis B and treatment for chronic hepatitis delta. Our portfolio of broad, potent investigational monoclonal antibodies also targets influenza A and B viruses, COVID-19, respiratory syncytial virus/human metapneumovirus and human papillomavirus, and our investigational T cell vaccine aims to prevent HIV. Explore our full pipeline: https://bit.ly/3tr7FPm We collaborate with some of the world’s leaders in industry as well as government agencies and non-profit organizations enabling us to rapidly advance cutting-edge scientific discoveries and innovative technologies with the potential to benefit people around the world. We are proud to have been ranked the fastest-growing company in North America on the 2022 Deloitte Technology Fast 500™. Join us as we pursue our mission to transform lives. It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir’s recruiting process: https://bit.ly/461EgJN
- Website
-
http://www.vir.bio
Externer Link zu Vir Biotechnology, Inc.
- Branche
- Biotechnologieforschung
- Größe
- 501–1.000 Beschäftigte
- Hauptsitz
- San Francisco, California
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2016
Orte
-
Primär
1800 Owens St
Suite 900
San Francisco, California 94158, US
-
Via Mirasole 1
Bellinzona, Ticino 6500, CH
Beschäftigte von Vir Biotechnology, Inc.
Updates
-
Join our Chief Medical Officer, Mark Eisner, for a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference where he will share perspectives on Vir’s Hepatitis Delta and B programs. ➡️ Sign up here: https://lnkd.in/gHAxzPPZ
-
Nasdaq at Times Square lights up for Jason O'Byrne, Vir’s new Executive Vice President and CFO as he joins us this week. We are #VirProud to welcome him as part of the team and wish him every success. Welcome, Jason!
-
Congratulations and proficiat to our CEO Marianne De Backer, MSc, PhD, MBA on her recognition as Ghent University’s Alumnus of the Year 2024! We are #VirProud about this recognition of Marianne’s career and testament to her #leadership, dedication, and contributions to accelerating innovation for those who need it most.
Stories are powerful: through them we share, we inspire, and we organize to take action, making the impossible a reality. I had the opportunity to share my story yesterday as I received the Alumnus of the year 2024 award from Rector Rik Van De Walle at Universiteit Gent. It was an honor for me to be recognized for my career and to share some of the moments that have shaped me into who I am today, some of which happened right at this university. After this chance to reflect and celebrate with peers, mentors, and family, it's time to get back to work: patients are waiting, and we're on a mission to change that at Vir Biotechnology, Inc.!
-
Vir welcomes Dr. Mika Kakefuda Derynck as Executive Vice President of Therapeutic Oncology. She brings over 30 years of experience in cancer research and drug development in areas of high unmet need and limited options for patients. Her focus is driving development of masking and other innovative technologies in oncology to demonstrate benefit and expedite approvals of immunotherapies for solid tumors. Read more about our expanded areas of focus: https://lnkd.in/gQQvnrYB
-
Curious about what Vir Biotechnology, Inc.'s exclusive worldwide license agreement with Sanofi means for us? Marianne De Backer, MSc, PhD, MBA reflects on the news. Read all about it here: https://lnkd.in/gnBcDN2h
It is an exhilarating week for Vir Biotechnology, Inc. and for me personally! I am excited to welcome a new team of skilled scientists to Vir with a passion to progress science for patients! We have successfully closed our exclusive worldwide license agreement with Sanofi. Beyond bolstering our clinical pipeline with three T cell engagers in #oncology, we are also complementing our world-class #antibody platform with the highly synergistic and pre-clinically validated PRO-XTEN #masking platform. The potential of these combined platforms in #cancer and #infectiousdisease is immense. I am already looking forward to the impact we will have as we work together to transform the lives of #patients. #PatientsAreWaiting #Tcellengagers #PoweringTheImmuneSystemToTransformLives #TeamVir
-
🌟 Exciting News at Vir Biotechnology! 🌟 We are pleased to announce the appointment of Jason O'Byrne as our new Chief Financial Officer effective Oct 02, 2024. To learn more about the experience and expertise Mr. O’Byrne will bring to Vir, please check out our press release: https://lnkd.in/g_BE4a9i #TeamVir #CFO
-
📣 NEWS 📣 Today we execute on our expanded strategy to consolidate our growth beyond #InfectiousDiseases. We are proud to bring on board three clinical-stage masked T-cell engagers with potential applications in #oncology and exclusive use of the proprietary PRO-XTEN platform in oncology and infectious disease. ➡️ Read about it here: https://lnkd.in/gnBcDN2h
-
Reminder: Join Marianne De Backer, MSc, PhD, MBA, tomorrow, September 5, for a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference. Sign up and join the webcast here: https://lnkd.in/gZiiG_xC
-
Tune in September 5 for a fireside chat with Marianne De Backer, MSc, PhD, MBA, at the Morgan Stanley 22nd Annual Global Healthcare Conference. Learn more here: https://lnkd.in/gnHDn4-3